Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Metabolic syndrome linked to greater COVID-19 severity
Individuals with metabolic syndrome who are hospitalized for COVID-19 may have a greater risk for more severe COVID-19 disease, including an elevated risk of in-hospital mortality, acute respiratory distress syndrome (ARDS), and intensive care unit (ICU) admission, a recent prospective study showed.
Metabolic syndrome linked to greater COVID-19 severity
21 Jan 2022Osteoporosis drug holidays tied to small rise in hip fracture risk
The risk for hip fracture slightly increases following osteoporosis drug holidays after long-term therapy with risedronate compared with alendronate, a study has found, adding that future research must examine how best to lessen such risk.
Osteoporosis drug holidays tied to small rise in hip fracture risk
21 Jan 2022PSOARING trials boost potential of tapinarof for plaque psoriasis
The nonsteroidal topical aryl hydrocarbon receptor (AHR)-modulating agent tapinarof 1% trumped a vehicle control cream in reducing the severity and manifestations of plaque psoriasis, according to the phase III PSOARING 1 and 2 trials.
PSOARING trials boost potential of tapinarof for plaque psoriasis
21 Jan 2022Aspirin does not cut death risk in hospitalized COVID-19 patients
Adding aspirin to usual care did not lead to a reduced mortality rate in patients hospitalized with COVID-19, according to a study by the RECOVERY* Collaborative Group.
Aspirin does not cut death risk in hospitalized COVID-19 patients
20 Jan 2022Sitafloxacin a promising treatment alternative for UTI
Oral sitafloxacin was just as effective and safe as levofloxacin for the treatment of complicated and uncomplicated urinary tract infections (UTIs) in adults, according to a phase III study from China.
Sitafloxacin a promising treatment alternative for UTI
20 Jan 2022Early remdesivir treatment lowers risk of COVID-19 progression
In the treatment of patients with COVID-19, administering remdesivir within 5 days of symptom onset appears to reduce the risk of progression to severe disease, as shown in a study.
Early remdesivir treatment lowers risk of COVID-19 progression
19 Jan 2022CATALYST sparks signals favouring namilumab for COVID-19
In the phase II proof-of-concept CATALYST trial comparing the GM-CSF* inhibitor namilumab and the TNF** inhibitor infliximab against usual care (UC), namilumab, but not infliximab, demonstrated signals for reducing inflammation in hospitalized patients with COVID-19 pneumonia.